by Brendon Nafziger
, DOTmed News Associate Editor | April 26, 2011
The Centers for Medicare and Medicaid Services said in a memo Tuesday it had enough evidence to justify paying for MRI scans of patients with the new MRI-safe pacemakers.
CMS said it was proposing to update the language in the NCD Manual to remove the contraindication for Medicare coverage of MRI scans in patients with the implantable devices, if the devices are approved by the Food and Drug Administration for use around MRI machines.
The update revises a Feb. 24 decision to cover MRI scans for Medicare beneficiaries with the MRI-safe pacemakers only if they were participating in a clinical trial.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
CMS said it was moved to reconsider its rules in February after receiving a letter from Medtronic Inc., the Finley, Minn.-based manufacturer of the RevoMRI SureScan Pacing System, the the first MRI-safe pacemaker
to go to market. The FDA approved the device in early February.
For the new evidence showing the safety of MRI scans with the new pacemakers, the agency cited a study provided by Medtronic, published in the January issue of Heart Rhythm. The study described a randomized control trial with 464 patients showing the safety of the device.
Currently, the RevoMRI pacemaker can only be used with a 1.5-Tesla scanner and only under certain conditions.
CMS said the reconsideration doesn't include a coverage determination for Medtronic's RevoMRI or other pacemakers or change other contraindications for MRI scans.
The new proposal comes at the end of a 30-day public comment period on the coverage changes, which closed earlier this month.